Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8145 - 8152 of 12089 results
Illinois Joins the Fray: Strengthens its Laws Around Data Breach Notification and Data Security
June 14, 2016| Blog| Viewpoint
CPSC Civil Penalties: A Divide Along Party Lines
June 14, 2016| News
Medical Device Updates: U.S. Food and Drug Administration (FDA) Practice Trends
June 14, 2016| Article| Viewpoint
Supreme Court Makes It Harder for Willful Infringers to Escape Punishment
June 14, 2016| Alert| Viewpoint
(Trade)Marking Your Territory in the US: A Guide for Non-US Companies
June 14, 2016| News
OTC Drug Regulatory Paradigm Open to Stakeholder Feedback Until July 10
June 14, 2016| Blog| Viewpoint
Canadian Court Holds That Evidentiary Requirement For Leave To File Securities Class Action Is "Not A Low Bar"
June 14, 2016| Blog| Viewpoint
The Department of Labor’s 2016 Final Fiduciary and Conflict of Interest Regulations: The Principal Transactions Exemption
June 13, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|